Cyprotex Share Discussion Threads

[spekky] 24/12/2010 07:27

Thank you Santa Baxter and your good elves. ;-))

[cotton4] 24/12/2010 07:11

Trading Statement
Share this article

TIDMCRX

RNS Number : 5637Y

Cyprotex PLC

24 December 2010

24 December 2010

Cyprotex PLC

("Cyprotex" or "the Company")

Trading Update

Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, announces that the Company has made solid progress following the integration of Apredica and Cellumen. The Directors expect full year results for the period ended 30 December 2010 to be in line with market expectations as described in the most recently published analyst note of 23 November 2010.

Dr Anthony D Baxter, Cyprotex's Chief Executive Officer, said:

"Following our acquisition of Apredica in August and the introduction of our new CellCiphr(TM) toxicology suite, we are pleased to report good, steady progress in trading. We expect our numbers to be in line with market expectations and our ongoing investment programme reflects our continued confidence in the future prospects for Cyprotex."

Very encouraging for 2011

[redprince] 23/12/2010 17:08

Husbod - in all seriousness i dont use the Mrs for cgt purposes - well not yet anyway!Still at work - well for another 22 mins to be precise.

[orvil] 22/12/2010 17:05

old crow-from one bird to another -the difference being you probably can operate without a hand up your backside-I wish all crx shareholders a prosperous future.

[cotton4] 22/12/2010 16:53

And to you too, you crafty bird

[old crow] 22/12/2010 16:08

The Crows wish you all the very best.

Keep Crowing.

[cotton4] 22/12/2010 10:46

Lets hope so. There can't be many excuses out there now.

[redprince] 22/12/2010 10:43

Hi Cotton4 - i trust you are well despite the weather?Married life is grand thanks - i really can`t complain.Only change is my wife now owns a lot of shares in small cap co`s like this except she doesn`t know it!!

Would be nice to see some really good news on next results and a corresponding lift in the sp!!!

[cotton4] 22/12/2010 10:25

Long time no hear from you Red. Glad to see you're still on board. How's married life treating you?

[spekky] 22/12/2010 10:24

HAPPY CHRISTMAS ALL

[redprince] 22/12/2010 10:19

Happy Christmas all and a prosperous New Year!

[cotton4] 22/12/2010 10:17

Looking back on 2010, it certainly has been an interesting year. From a muted takeover attempt through to acquisition of Apredica/Cellumen.
From an share price point of view, probably dissapointing but we go into 2011 with double the customers we had this time last year, a presence in America an increased sales team both in America and Europe and a step into the world of toxicology. We are hiring both here and America. The building blocks are being put in place. All we need now is visibility re sales and a strategy from the board going forward.

All the best CRX holders for 2011.

[buywell2] 21/12/2010 23:29

The predictive side of Cyprotex has long been a bone of contention with me

There used to be circa 8 software bods working on it the old CEO informed me

It seems to be run as an 'attractant' to get ADMET clients and diferentiate it from other pure ADMET companies.

I see now a new vacancy which appertains to this side of the business....so

Does this mean we are expanding predictive offerings based upon clients wanting our services ?

Mathematical Modeller


Job Purpose

We are seeking talented individuals with a strong background in mathematical modelling/mathematics to participate in the development of cutting edge applications for use in the drug discovery and development process. The immediate aims are the development of:

1. Simulation models for predicting pharmacokinetics (PK) and pharmacodynamics (PD) of novel drug candidates (PBPK and PBPK/PD models) from appropriate in vitro ADME and receptor-binding data generated during drug discovery.
2. Bioinformatics/simulation models for predicting in vivo toxicity of novel drug candidates from high-content screening (HCS) data generated during drug discovery.

The successful applicants will work either at our Macclesfield, U.K. or Boston, U.S.A. site alongside laboratory staff to develop integrated in vitro/in silico methodologies for the prediction of overall PK/PD behaviour and in vivo safety of novel pharmaceuticals.

Experience

Candidates should have experience gained during, or subsequent to completing, a Ph.D., of creating and running mathematical models of physiological, biochemical, biological, chemical or engineering systems. Aptitude, flexibility and demonstrable ability to deliver quality work are more important than any particular modelling skill-set or experience. Suitable candidates may come from a simulation modelling, bioinformatics, machine-learning or other background.

Accountabilities

• Development of mathematical models for the prediction of in vivo ADMET, for the company's internal research projects and on behalf of customers.
• Supporting commercial activities that involve the deployment of in silico solutions, namely: technical support for commercial software (e.g. Cloe® PK, CellCiphr®); running and interpreting simulation models for combined in vitro, in silico projects.
• Participating in collaborative research projects with universities, SME's and big pharma funded by external bodies (e.g. EU FP6, 7; IMI, etc).
• Contributing to the Company's output of peer-reviewed publications on in silico methodologies.
• Monitoring and assessing cutting-edge development in in vitro and in silico methods in ADME/PK/PD.
• Supporting the preparation of project development plans, budgets and reports.

Knowledge, Skills & Competencies

Essential:
• A PhD in a scientific, mathematical or engineering discipline.
• A high degree of numeracy.
• Adaptability and flexibility.
• Significant experience of mathematical modelling applied to complex systems
• An interest in modelling biochemical or physiological systems.
• Significant experience with MATLAB or similar modelling software.
• Ability to work as part of a team.
• Confidence to work on your own initiative.
• Excellent oral and written communication and presentation skills.

Desirable:
• Experience of drug discovery or drug development.
• Sound understanding of ADME, PK, PD and/or toxicology.
• Familiarity with Bayesian statistical techniques.
• Experience of computer programming, particularly in Python.
• Object-oriented programming skills.
• Knowledge of SQL.

Development Opportunities

With the recent acquisition of Apredica (www.apredica.com), and Cellumen technology (www.cellumen.com) Cyprotex develops and deploys a unique range of in silico and in vitro services and products to more than 500 customers worldwide working in drug discovery and development, agrochemistry and neutraceuticals. Within this dynamic commercial and research environment, the job-holders will have the opportunity to develop their scientific knowledge to cover this large and expanding range of services. provided by the company in experimental ADME screening, in vitro toxicology and software systems for the prediction of pharmacokinetics, pharmacodynamics and drug safety in vivo. It is also expected that they will be required to act in a consultative manner for our customers on specific client-driven projects.

Training will be available to complement existing skills with any additional expertise required for successful execution of the jobholder's accountabilities.

We expect that the jobholder will be able to enhance their publication record by contributing to publications in high-quality journals, and by presentation of original work at relevant scientific conferences.

Please apply with a curriculum vitae/résumé by 31st December to:

[e-mail]




I am of the opinion that the company should only offer services that pay their own way. Cash is going to be king for the next decade and needs to watched like a hawk.

If our predictive unit does not , then I think we should spend those resources upon what does, perhaps the next update will give us more detail.

A breakdown on 'ADME' .... 'T' .... within the USA .... UK ... plus how Cellumen is doing , and the 'predictive unit' numbers would be good

[buywell2] 21/12/2010 22:16

Don't think AZ will like that thought even if read on a BB

Note the contract win with my number 2 choice

Cyprotex trading updates were done in oct/november in the last 4 years, the date getting later each year.

[cotton4] 21/12/2010 07:52

See AstraZenaka takes knock of £285m. Begs question if this could have been avoided or substantially reduced with the use of services provided by CRX.

[spekky] 20/12/2010 13:44

Cotton4

Dont forget theres still 3 vacancies at Apredica (per website).An update would be nice I agree.

[cotton4] 20/12/2010 13:24

Simply because we got one last year.

[rickrijsdijk] 20/12/2010 13:12

Why do you think we'll get an update in January?

[cotton4] 20/12/2010 13:08

I'd like to think that CRX has a bit more visibility re sales going forward. If not we certainly have more overheads going into 2011. IMO it would not be like CRX to hire staff just for the sake of it, so hopefully we will get a positive update in January.

[rickrijsdijk] 20/12/2010 13:05

Hi guys, happy to help to keep the thread alive, but I have not much to add. I hold a small shareholding (65k) and follow the BB. Thanks everyone for posting, keep doing so. main questions are: why no updates and why is the shareprice not moving (ever)

[old crow] 20/12/2010 12:09

Thanks Cotton for keeping it alive.

[cotton4] 20/12/2010 11:00

New lab assistant on board? Vacancies now down to 2.